Oncology

Dr. Frank Smith joins XenoSTART to lead its preclinical unit, aiming to leverage its vast patient-derived model library to speed up oncology drug development.

Fresh off strong 2025 earnings, AtriCure will detail its growth strategy and innovative cardiac portfolio at a major life sciences conference.

Facing SEC delays, Aptose Biosciences secures an $11.1M lifeline from its acquirer, Hanmi, highlighting financial strain as the critical deal moves forward.

A pivotal trial for a rare muscle disease failed its main goal, but promising data in a specific patient group offers a new, complex path forward.

Avacta's pre|CISION therapy shows faster, more potent, and more selective tumor targeting than Enhertu in an AI-driven study, paving the way for 2026 trials.

Caidya appoints veteran Michael Clay as COO, leveraging his deep Asia-Pacific expertise to scale operations and solidify its position in the CRO market.

With promising data in cancer and eczema, all eyes are on Corvus Pharmaceuticals as it presents its lead drug at a major healthcare conference this week.

As Legacy Community Health embarks on a historic expansion, new COO Aaron Stewart is tasked with steering Texas's largest FQHC to serve more communities.

A former Regeneron exec who built a blockbuster drug joins a medtech startup, signaling a major push to disrupt the multi-billion dollar chemo-port market.

Celebrating 10 years, Maryland's first proton center has treated 6,000 patients by blending advanced technology with a unique model for affordable care.

Acquiring Complete Genomics, Swiss Rockets unveils its CoolMPS 600, a bid to democratize long-read sequencing with breakthrough cost and accuracy.

BioVie faces a pivotal moment, touting breakthrough drugs for Alzheimer's and cirrhosis while navigating clinical setbacks and financial pressures.

At a key industry summit, Sutro Biopharma showcases its next-gen ADC platform, designed to overcome treatment resistance with "supercharged" dual-payload drugs.

As Lyell presents at three major investor conferences, the biotech's pipeline, financial health, and future in cancer therapy are under scrutiny.

Verrica Pharmaceuticals heads to a key investor conference with strong YCANTH sales, a promising pipeline for warts and skin cancer, and high expectations.

With a soaring stock, $300M in new funding, and strong clinical data, Monte Rosa is set to showcase its novel disease-fighting drug platform.

C4 Therapeutics begins a crucial study for its oral protein degrader, cemsidomide, offering new hope for heavily treated multiple myeloma patients.

With a key drug in trials and a pipeline nearing the clinic, Foghorn Therapeutics brings in a seasoned financial leader to navigate its path to market.

The biotech firm slashed a major acquisition hurdle in a deal with HealthCare Royalty, signaling strong confidence in its cancer drug ZYNLONTA's future.

With stockholder approval, Abbott's acquisition of Exact Sciences is set to reshape the cancer diagnostics landscape and accelerate early detection.